Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Core Insights - Alpha Tau Medical Ltd. has received regulatory marketing approval for its Alpha DaRT cancer therapy in Japan, marking the first approval outside of Israel [1][2][3] - The approval is a significant milestone for the company and reflects strong collaboration with Japanese regulators and clinical societies [1][3] Regulatory Approval - The Shonin approval process in Japan is known for its rigor, requiring a review by the Pharmaceuticals and Medical Devices Agency (PMDA) [2] - As part of the approval, Alpha Tau will conduct a post-market surveillance study involving 66 patients across five clinical centers in Japan to assess the safety and clinical performance of Alpha DaRT [2] Clinical Significance - The Alpha DaRT platform is designed to deliver intra-tumoral alpha-emitting radiotherapeutics, which has shown promise in treating unresectable locally advanced or locally recurrent head and neck cancer [1][7] - The therapy aims to provide a new treatment option for patients who have not responded to conventional therapies, potentially expanding the range of treatment options available [4][5] Collaboration and Future Plans - Alpha Tau plans to work closely with Japanese clinicians to complete the post-market surveillance study and generate high-quality clinical data [3] - The company anticipates discussions with the MHLW regarding potential reimbursement approaches for Alpha DaRT in Japan, aiming for broader clinical evaluation and potential studies for additional tumor types [3] Company Background - Alpha Tau Medical Ltd. was founded in 2016 and focuses on the research, development, and commercialization of Alpha DaRT for solid tumors [6] - The technology was developed by researchers from Tel Aviv University and aims to deliver targeted alpha-irradiation to tumors while sparing healthy tissue [7]